0001493152-26-014132
SEC filingMatinas BioPharma reported a meaningful reduction in operating and net losses for FY2025 versus FY2024, reflecting cost discipline following the MAT2203 partnership termination — yet it remains fully dependent on external financing with no revenue and an explicit going concern qualification.
Management expects general and administrative expenses to decrease slightly in FY2026 relative to FY2025, confirming that austerity remains the primary lever available absent new capital or a strategic partner. The Company anticipates continuing to incur significant expenses and increasing operating losses for the foreseeable future — a direct consequence of its pre-revenue, development-stage status and the absence of near-term monetization pathways for its pipeline. Without additional funding or a partnership, the ability to sustain operations past the next twelve months is not assured.